ArticleFrontiers in microbiology2026
Age-specific alterations in gut microbiota-plasma metabolome networks in first-episode, drug-naïve major depressive disorder: adolescent versus adult patients.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) exhibits pronounced age-related pathophysiological heterogeneity, yet the distinct signatures of the microbiota-gut-brain (MGB) axis between adolescent and adult patients remain inadequately characterized. This study aimed to elucidate age-specific MGB axis dysregulation by integrating gut microbiota profiling, plasma metabolomics, and their interactive networks in first-episode, drug-naïve MDD patients across these two developmental stages. Methods: We enrolled 62 first-episode, drug-naïve MDD patients (28 adolescents, 34 adults) alongside 43 age- and sex-matched healthy controls (22 adolescents, 21 adults). Fecal samples underwent 16S rRNA gene sequencing, while plasma was analyzed via untargeted metabolomics. Comprehensive bioinformatics and network analyses were applied to map microbial compositional shifts, metabolic perturbations, and microbe-metabolite crosstalks. Results: Integrated multi-omics analysis revealed distinct age-specific gut microbiota and plasma metabolome signatures in TMDD and AMDD compared with their age-matched controls. ① Microbiota: Beyond shared depletion of Firmicutes and butyrate-producing genera (Anaerobutyricum, Blautia), TMDD exhibited more extensive remodeling. Characterized by increased (Chao1 index, Conclusion: Our findings suggest that first-episode, drug-naïve MDD patients display distinct age-specific dysregulation of the microbiota-gut-plasma metabolome axis. The non-overlapping pathological signatures, a "development-nutrition-metabolic" disturbance pattern in adolescents versus an "energy metabolism-oxidative stress" pattern in adults, underscore the pronounced pathophysiological heterogeneity of MDD across the lifespan. These preliminary observations indicate that future diagnostic biomarkers and therapeutic interventions, particularly microbiota-targeted strategies, should be precisely tailored to the biological profiles of different age groups. However, given the exploratory nature of this subtyping, larger independent cohort studies are warranted to validate these findings before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.